MLchartDataset catalogue

IL-2 fusion protein PTX-912

Term · Oncology and biomedicine · MLC-T-ONC-014356

A fusion protein consisting of the cytokine interleukin-2 (IL-2) fused to an as of yet not fully elucidated protein, with potential immunopotentiating and antineoplastic activities. Upon administration, IL-2 fusion protein PTX-912 targets and binds to IL-2 receptors, and activates IL-2 receptor-mediated signaling in immune cells. This activates cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). This leads to T-cell-mediated cytotoxic immune responses against tumor cells and inhibits tumor cell proliferation.

Table 1. Record
IdentifierMLC-T-ONC-014356
FieldOncology and biomedicine
ReferencesNational Cancer Institute Thesaurus (CC BY 4.0)
Record as JSON
{
  "id": "MLC-T-ONC-014356",
  "term": "IL-2 fusion protein PTX-912",
  "field": "Oncology and biomedicine",
  "definition": "A fusion protein consisting of the cytokine interleukin-2 (IL-2) fused to an as of yet not fully elucidated protein, with potential immunopotentiating and antineoplastic activities. Upon administration, IL-2 fusion protein PTX-912 targets and binds to IL-2 receptors, and activates IL-2 receptor-mediated signaling in immune cells. This activates cytotoxic T lymphocytes (CTLs) and natural killer (NK) cells, and induces expression of certain cytotoxic cytokines, such as interferon-gamma (IFNg) and transforming growth factor-beta (TGFb). This leads to T-cell-mediated cytotoxic immune responses against tumor cells and inhibits tumor cell proliferation.",
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/il-2-fusion-protein-ptx-912/"
}

Record 9,007 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.